PREVIOUS
✖
First AI Tool for Liver Disease
December 17 , 2025
15 hrs 0 min
48
0
- AIM-NASH is the first AI tool qualified by the U.S. Food and Drug Administration (FDA) for assessing severe fatty liver disease.
- It analyses liver biopsy images to detect fat accumulation, inflammation, and scarring in metabolic dysfunction-associated steatohepatitis (MASH).
- The tool uses deep learning algorithms to generate standardized scores reviewed by doctors for final diagnosis.
- FDA qualification will accelerate MASH clinical trials, reduce trial timelines, and lower reliance on multiple human readings.
- AIM-NASH demonstrates the growing role of AI in drug development while maintaining human oversight for accuracy.
Leave a Reply
Your Comment is awaiting moderation.